| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Oropouche Virus Antibody (IgM)
Test Code16766
CPT Codes
86790<br><strong>This test is not available for New York patient testing.</strong>
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Lipemia • Icteric
Methodology
Immunoassay (IA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Thurs; Report available: 1-7 days
Clinical Significance
This immunoassay is intended for the qualitative detection of IgM antibodies to Oropouche virus in serum from patients suspected of having acute infection. A positive IgM result can help support diagnosis in a patient with the appropriate risk factors presenting with signs and symptoms consistent with Oropouche virus disease (Oropouche fever). If additional testing is needed, please contact the public health department.
Oropouche virus disease is a vector-borne infectious disease that is primarily transmitted through the bite of an infected midge or mosquito. The disease is found in South America and the Caribbean. Increasing cases have been observed, including in US travelers, due to several outbreaks occurring outside known endemic areas. Symptomatic individuals typically present with fever, severe headache, chills, muscle aches, and joint pain with relapsing symptoms. These symptoms may overlap with other vector-borne illnesses in the same geographic regions, such as dengue, chikungunya, zika, or malaria. Complications related to neuroinvasive disease, Guillain-Barre syndrome, and vertical transmission in pregnant women has been reported.
Although there is no specific treatment for Oropouche virus disease, diagnostic testing is recommended to inform clinical management. Viremia is highest during the first 7 days post symptom onset, therefore direct detection of viral RNA using a molecular assay should be performed during this timeframe. Antibodies are typically detected starting 1 week post symptom onset. False negatives can occur early during infection before seroconversion; therefore, paired acute (within 2 weeks of illness) and convalescent sera can be tested.
References:
1. Wesselmann K, et al. Lancet infectious Diseases. 2024;24 :e439-452
2. Updated Interim Guidance for Health Department on Testing and Reporting for Oropouche Virus Disease. https://www.cdc.gov/oropouche/php/reporting/index.html Last updated April 10, 2025.
Oropouche virus disease is a vector-borne infectious disease that is primarily transmitted through the bite of an infected midge or mosquito. The disease is found in South America and the Caribbean. Increasing cases have been observed, including in US travelers, due to several outbreaks occurring outside known endemic areas. Symptomatic individuals typically present with fever, severe headache, chills, muscle aches, and joint pain with relapsing symptoms. These symptoms may overlap with other vector-borne illnesses in the same geographic regions, such as dengue, chikungunya, zika, or malaria. Complications related to neuroinvasive disease, Guillain-Barre syndrome, and vertical transmission in pregnant women has been reported.
Although there is no specific treatment for Oropouche virus disease, diagnostic testing is recommended to inform clinical management. Viremia is highest during the first 7 days post symptom onset, therefore direct detection of viral RNA using a molecular assay should be performed during this timeframe. Antibodies are typically detected starting 1 week post symptom onset. False negatives can occur early during infection before seroconversion; therefore, paired acute (within 2 weeks of illness) and convalescent sera can be tested.
References:
1. Wesselmann K, et al. Lancet infectious Diseases. 2024;24 :e439-452
2. Updated Interim Guidance for Health Department on Testing and Reporting for Oropouche Virus Disease. https://www.cdc.gov/oropouche/php/reporting/index.html Last updated April 10, 2025.
